Ayla Annac, CEO and Co-Founder, InvivoSciences shines light on the next generation of precision medicine and explains how IVS is personalizing the drug development process with patient-derived and gene-edited human samples.\xa0 The company's Novel Heart Tissue on a chip platform NuHeart\u2122 enables rapid identification of the safety and efficacy profile of a given treatment for a specific patient group.\xa0 IVS is saving time and money in developing new therapies while increasing the success rate of approval for cardio safe therapies.
#COVID19 #ChronicHeartFailure
\xa0